Once-yearly zoledronic acid in older men compared with women with recent hip fracture

Journal of the American Geriatrics Society

Volumn 59, Issue 11, 2011, Pages 2084-2090

  Boonen, Steven ^a   Orwoll, Eric ^b   Magaziner, Jay ^c   Colõn Emeric, Cathleen S ^d   Adachi, Jonathan D ^e   Bucci Rechtweg, Christina ^f   Haentjens, Patrick ^g   Kaufman, Jean Marc ^h   Rizzoli, Rene ^a,i   Vanderschueren, Dirk ^a   Claessens, Frank ^a   Sermon, An ^j   Witvrouw, Richard ^k   Milisen, Koen ^j   Su, Guoqin ^f   Lyles, Kenneth W ^c,l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY   (United States)

^e MCMASTER UNIVERSITY   (Canada)

^f NOVARTIS PHARMA AG   (Switzerland)

^g UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^h GHENT UNIVERSITY HOSPITAL   (Belgium)

ⁱ GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^j UNIVERSITY OF LEUVEN   (Belgium)

^k DEPARTMENT OF CARDIOLOGY   (Belgium)

^l DURHAM VA MEDICAL CENTER   (United States)

more..

Author keywords

bone mineral density; hip fracture; men; once yearly; osteoporosis

Indexed keywords

ANTICONVULSIVE AGENT; CALCIUM; COLECALCIFEROL; ERGOCALCIFEROL; PLACEBO; PREDNISONE; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AGED; ALCOHOLISM; ARTICLE; ASTHMA; BONE DENSITY; BONE MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG SAFETY; FEMALE; FEMUR NECK; HIP FRACTURE; HUMAN; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; SECONDARY OSTEOPOROSIS; SEX DIFFERENCE; VITAMIN SUPPLEMENTATION;

ABSORPTIOMETRY, PHOTON; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HIP FRACTURES; HUMANS; IMIDAZOLES; INCIDENCE; INJECTIONS, INTRAVENOUS; MALE; OSTEOPOROSIS; PREVALENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 81755166222     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03666.x     Document Type: Article

References (32)

1. Siddiqui NA, Shetty KR, Duthie EH, Jr,. Osteoporosis in older men: Discovering when and how to treat it. Geriatrics 1999; 54: 20.
2. Center JR, Nguyen TV, Schneider D, et al. Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet 1999; 353: 878-882.
3. Forsen L, Sogaard AJ, Meyer HE, et al. Survival after hip fracture: Short-and long-term excess mortality according to age and gender. Osteoporos Int 1999; 10: 73-78.
4. Johnell O, Kanis J, Gullberg G,. Mortality, morbidity, and assessment of fracture risk in male osteoporosis. Calcif Tissue Int 2001; 69: 182-184.
5. Vestergaard P, Rejnmark L, Mosekilde L,. Has mortality after a hip fracture increased? J Am Geriatr Soc 2007; 55: 1720-1726.
6. Cooper C, Campion G, Melton LJ, 3rd,. Hip fractures in the elderly: A world-wide projection. Osteoporos Int 1992; 2: 285-289.
7. Kanis JA, Oden A, Johnell O, et al. The components of excess mortality after hip fracture. Bone 2003; 32: 468-473.
8. Trombetti A, Herrmann F, Hoffmeyer P, et al. Survival and potential years of life lost after hip fracture in men and age-matched women. Osteoporos Int 2002; 13: 731-737.
9. Amin S, Felson DT,. Osteoporosis in men. Rheum Dis Clin North Am 2001; 27: 19-47.
10. Bliuc D, Nguyen ND, Milch VE, et al. Mortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and women. JAMA 2009; 301: 513-521.
11. Campion JM, Maricic MJ,. Osteoporosis in men. Am Fam Physician 2003; 67: 1521-1526.
12. Colõn-Emeric CS, Sloane R, Hawkes WG, et al. The risk of subsequent fractures in community-dwelling men and male veterans with hip fracture. Am J Med 2000; 109: 324-326.
13. Kiebzak GM, Beinart GA, Perser K, et al. Undertreatment of osteoporosis in men with hip fracture. Arch Intern Med 2002; 162: 2217-2222.
14. Vestergaard P, Rejnmark L, Mosekilde L,. Osteoporosis is markedly underdiagnosed: A nationwide study from Denmark. Osteoporos Int 2005; 16: 134-141.
15. Feldstein A, Elmer PJ, Orwoll E, et al. Bone mineral density measurement and treatment for osteoporosis in older individuals with fractures: A gap in evidence-based practice guideline implementation. Arch Intern Med 2003; 163: 2165-2172.
16. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822.
17. Lyles KW, Colõn-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 2007; 357: 1799-1809.
18. Szulc P, Munoz F, Marchand F, et al. Semiquantitative evaluation of prevalent vertebral deformities in men and their relationship with osteoporosis: The MINOS study. Osteoporos Int 2001; 12: 302-310.
19. Hui SL, Gao S, Zhou XH, et al. Universal standardization of bone density measurements: A method with optimal properties for calibration among several instruments. J Bone Miner Res 1997; 12: 1463-1470.
20. Cockcroft DW, Gault MH,. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
21. Colõn-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 2010; 25: 91-97.
22. Orwoll E, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70 mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study. J Bone Miner Res 2010; 25: 2239-2250.
23. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med 2000; 343: 604-610.
24. Boonen S, Orwoll ES, Wenderoth D, et al. Once-weekly risedronate in men with osteoporosis: Results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res 2009; 24: 719-725.
25. Mackey DC, Lui LY, Cawthon PM, et al. High-trauma fractures and low bone mineral density in older women and men. JAMA 2007; 298: 2381-2388.
26. European Medicines Agency 2006. Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. CPMP/EWP/552/95 Rev. 2 [on-line]. Available at Accessed May 31, 2011.
27. Kannegaard PN, van der Mark S, Eiken P, et al. Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing 2010; 39: 203-209.
28. Haentjens P, Magaziner J, Colõn-Emeric CS, et al. Meta-analysis: Excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380-390.
29. Beaupre LA, Morrish DW, Hanley DA, et al. Oral bisphosphonates are associated with reduced mortality after hip fracture. Osteoporos Int 2011; 22: 983-991.
30. Bilezikian JP,. Osteoporosis in men. J Clin Endocrinol Metab 1999; 84: 3431-3434.
31. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): A multicentre, double-blind, double-dummy, randomised controlled trial. Lancet 2009; 373: 1253-1263.
32. Zhong ZM, Chen JT,. Anti-fracture efficacy of risedronic acid in men: A meta-analysis of randomized controlled trials. Clin Drug Investig 2009; 29: 349-357.